Sign in
Taking peoplePhase 1/2

Phase Ⅰ/Ⅱa Trial Evaluating Intravenous hUC-MSCs Injection for Safety, Tolerability and Efficacy in Patients With POI

Key facts

Who runs it
Shenzhen Wingor Biotechnology Co., Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 1/2
People taking part
59 people, planned
Started
3 Aug 2026
Expected to end
2 Aug 2029
Type of study
Interventional, 6 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • hUC-MSCs Injection (Phase I)
  • hUC-MSCs Injection (Phase IIa)
  • Placebo
Record updated
20 August 2026

Who can take part

Age
18 years to 40 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Aged 18 to 40 years at the time of signing the informed consent form (exclusive of the boundary values)
  • Meet the diagnostic criteria specified in the Expert Consensus on Clinical Diagnosis and Treatment of Premature Ovarian Insufficiency (2023 Edition): oligomenorrhea (menstrual cycle longer than 35 days) or amenorrhea for more than 4 months, with basal serum follicle-stimulating hormone (FSH) > 25 U/L (tested on Days 2-4 of the menstrual cycle or during amenorrhea, at least twice with an interval of ≥4 weeks)
  • Satisfy one of the following two criteria:; Total number of antral follicles (AFC) with a diameter of 2-10 mm in bilateral ovaries < 5; Serum anti-Müllerian hormone (AMH) ≤ 7.85 pmol/L (equivalent to 1.1 ng/mL)
  • Have received standardized hormone replacement therapy (HRT) at a stable dose for ≥3 months prior to drug administration with stable hormone levels, and maintain stable HRT per medical advice throughout the trial (within 24 weeks after enrollment)
  • Have no fertility requirements
  • Agree to use effective contraceptive measures throughout the trial period (such as complete abstinence, condoms, cervical caps plus spermicides, intrauterine devices, etc.)
  • Negative serum β-hCG test result during the screening period (to rule out pregnancy)
  • Fully understand the trial information and sign the informed consent form

Who cannot take part

  • Subjects receiving or planning to use the following medications during the trial: oral or systemic corticosteroids, danazol, anticoagulants, Chinese herbal medicines or botanical supplements that may affect hormone levels or ovarian function
  • Participation in another clinical trial within the past 3 months, or receipt of other cell therapies (excluding blood transfusion)
  • Subjects with thyroid disorders (hypothyroidism/hyperthyroidism or thyroid malignant tumors) or resistant ovary syndrome (ROS)
  • Subjects with abnormal female karyotypes (e.g., Turner syndrome, Fragile X syndrome)
  • Positive serology tests (HBV antibody, HCV antibody, HIV antibody, syphilis). Exceptions: HBV carriers, patients with stable HBV after drug treatment (HBV DNA titer ≤500 IU/mL or copies <1000 copies/mL), and patients with cured HCV (negative HCV RNA test) may be enrolled if deemed eligible by the investigator
  • History of malignant tumors
  • Uncontrolled diabetes, hypertension (>150/100 mmHg), heart disease, etc
  • Any other conditions judged by the investigator to render the subject unsuitable for participation in this study
  • History of hypersensitivity to human serum albumin
  • Subjects with contraindications or cautions for estrogen use, including known or suspected breast cancer, endometrial cancer, other known or suspected sex hormone-dependent malignancies, active venous or arterial thromboembolic diseases within the last 6 months, undiagnosed abnormal genital bleeding, severe hepatic or renal insufficiency [serum aspartate aminotransferase (AST) >3×ULN, serum alanine aminotransferase (ALT) >3×ULN, estimated glomerular filtration rate (eGFR) <60 mL/min], etc
  • Subjects with primary amenorrhea
  • Pregnant or breastfeeding subjects

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 40 years old?

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

A Phase I/IIa clinical study evaluating the safety, tolerability and efficacy of intravenously administered human umbilical cord mesenchymal stem cell (hUC-MSCs) injection in patients with premature ovarian insufficiency (POI).

Read full original descriptionShow less

The primary objective of the Phase I dose-escalation stage is to assess the safety and tolerability of intravenous infusion of hUC-MSCs injection for the treatment of POI, and to determine the recommended phase II dose (RP2D) for the Phase IIa clinical trial.

The primary objective of the Phase IIa dose-expansion stage is to evaluate the efficacy of intravenous infusion of hUC-MSCs injection in POI treatment, and to generate data to support pivotal/confirmatory clinical trials.

The 6 groups in the trial

  • Phase I, Dose Cohort 1Treatment being tested

    Human Umbilical Cord Mesenchymal Stem Cells Injection

    Treatment: hUC-MSCs Injection (Phase I)

  • Phase I, Dose Cohort 2Treatment being tested

    Human Umbilical Cord Mesenchymal Stem Cells Injection

    Treatment: hUC-MSCs Injection (Phase I)

  • Phase I, Dose Cohort 3Treatment being tested

    Human Umbilical Cord Mesenchymal Stem Cells Injection

    Treatment: hUC-MSCs Injection (Phase I)

  • Phase IIa, Medium-Dose CohortTreatment being tested

    Human Umbilical Cord Mesenchymal Stem Cells Injection

    Treatment: hUC-MSCs Injection (Phase IIa)

  • Phase IIa, High-Dose CohortTreatment being tested

    Human Umbilical Cord Mesenchymal Stem Cells Injection

    Treatment: hUC-MSCs Injection (Phase IIa)

  • Phase IIa, Placebo CohortPlacebo, for comparison

    Multiple Electrolytes Injection

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase Ⅰ/Ⅱa Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Intravenous Injection of Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSCs) in Patients With Premature Ovarian Insufficiency (POI)
Criteria questions
Built from NCT07775391, who can take part
Record updated
20 August 2026